Vaishalee P. Kenkre

3.3k total citations · 1 hit paper
37 papers, 456 citations indexed

About

Vaishalee P. Kenkre is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Vaishalee P. Kenkre has authored 37 papers receiving a total of 456 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pathology and Forensic Medicine, 24 papers in Genetics and 14 papers in Oncology. Recurrent topics in Vaishalee P. Kenkre's work include Lymphoma Diagnosis and Treatment (28 papers), Chronic Lymphocytic Leukemia Research (23 papers) and Viral-associated cancers and disorders (10 papers). Vaishalee P. Kenkre is often cited by papers focused on Lymphoma Diagnosis and Treatment (28 papers), Chronic Lymphocytic Leukemia Research (23 papers) and Viral-associated cancers and disorders (10 papers). Vaishalee P. Kenkre collaborates with scholars based in United States, Switzerland and Canada. Vaishalee P. Kenkre's co-authors include Brad S. Kahl, Andrew D. Zelenetz, Jacob D. Soumerai, Qing Cao, Wendy Stock, Umar Farooq, Veronika Bachanová, Sonali M. Smith, Judith A. Varner and Deepa Jagadeesh and has published in prestigious journals such as Science, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Vaishalee P. Kenkre

34 papers receiving 448 citations

Hit Papers

JAK inhibition enhances checkpoint blockade immunotherapy... 2024 2026 2024 25 50 75
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
    2024 77 citations Jaroslav Žák, Brett S. Marro et al. Science profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vaishalee P. Kenkre United States 13 260 258 208 120 78 37 456
Yuqin Song China 10 206 0.8× 231 0.9× 202 1.0× 108 0.9× 54 0.7× 65 443
Emanuele Cencini Italy 13 164 0.6× 281 1.1× 262 1.3× 218 1.8× 103 1.3× 55 535
Maria Delioukina United States 13 308 1.2× 426 1.7× 168 0.8× 168 1.4× 63 0.8× 33 652
Gottfried von Keudell United States 13 243 0.9× 293 1.1× 151 0.7× 104 0.9× 47 0.6× 46 560
Guido Parvis Italy 13 197 0.8× 241 0.9× 152 0.7× 56 0.5× 90 1.2× 27 437
Greg Dueck Canada 9 344 1.3× 475 1.8× 229 1.1× 168 1.4× 40 0.5× 13 570
Finlay MacDougall United Kingdom 7 352 1.4× 374 1.4× 166 0.8× 302 2.5× 98 1.3× 13 680
Dominique Penther France 12 117 0.5× 239 0.9× 258 1.2× 108 0.9× 122 1.6× 32 440
Junji Hiraga Japan 8 185 0.7× 266 1.0× 142 0.7× 102 0.8× 79 1.0× 17 464
Haiwen Huang China 11 234 0.9× 203 0.8× 122 0.6× 121 1.0× 100 1.3× 43 491

Countries citing papers authored by Vaishalee P. Kenkre

Since Specialization
Citations

This map shows the geographic impact of Vaishalee P. Kenkre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vaishalee P. Kenkre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vaishalee P. Kenkre more than expected).

Fields of papers citing papers by Vaishalee P. Kenkre

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vaishalee P. Kenkre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vaishalee P. Kenkre. The network helps show where Vaishalee P. Kenkre may publish in the future.

Co-authorship network of co-authors of Vaishalee P. Kenkre

This figure shows the co-authorship network connecting the top 25 collaborators of Vaishalee P. Kenkre. A scholar is included among the top collaborators of Vaishalee P. Kenkre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vaishalee P. Kenkre. Vaishalee P. Kenkre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Žák, Jaroslav, Brett S. Marro, Kristi Marquardt, et al.. (2024). JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science. 384(6702). eade8520–eade8520. 77 indexed citations breakdown →
2.
Soumerai, Jacob D., Catherine Diefenbach, Adam Asch, et al.. (2024). Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas. British Journal of Haematology. 204(5). 1762–1770. 3 indexed citations
3.
Bachanová, Veronika, J. Žák, Qing Cao, et al.. (2023). Phase 1 trial of Ruxolitinib combined with Nivolumab in patients relapsed/refractory Hodgkin lymphoma after failure of check‐point inhibitor (CPI). Hematological Oncology. 41(S2). 582–582. 3 indexed citations
4.
5.
Davids, Matthew S., Andrew W. Roberts, Vaishalee P. Kenkre, et al.. (2021). Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. Clinical Cancer Research. 27(17). 4690–4695. 48 indexed citations
6.
7.
Soumerai, Jacob D., Deepa Jagadeesh, Izidore S. Lossos, et al.. (2021). Initial results of the combination of PI3Kδ inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R/R) B-cell malignancies.. Journal of Clinical Oncology. 39(15_suppl). 7553–7553. 1 indexed citations
8.
Olszewski, Adam J., Izidore S. Lossos, Stephen D. Smith, et al.. (2020). Outcomes of Burkitt lymphoma (BL) managed in academic (Acad) or community (Comm) centers: real-world evidence (RWE) from 30 US sites.. Journal of Clinical Oncology. 38(15_suppl). 8043–8043.
9.
10.
Erbe, Amy K., Wei Wang, Lakeesha Carmichael, et al.. (2019). Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab. Journal for ImmunoTherapy of Cancer. 7(1). 70–70. 14 indexed citations
11.
Shah, Nirav N., Anikó Szabó, Raya Saba, et al.. (2018). Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. Clinical Lymphoma Myeloma & Leukemia. 19(2). 95–102. 9 indexed citations
12.
Otto, Mario, et al.. (2018). TCR αβ+/CD19+ cell depletion in haploidentical hematopoietic allogeneic stem cell transplantation: a review of current data. Leukemia & lymphoma. 60(3). 598–609. 8 indexed citations
13.
Nastoupil, Loretta J., Fontanet Bijou, Vincent Ribrag, et al.. (2018). Avadomide (CC-122), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma. Blood. 132(Supplement 1). 1602–1602. 7 indexed citations
14.
Epperla, Narendranath, Kwang Woo Ahn, Philippe Armand, et al.. (2017). Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. Biology of Blood and Marrow Transplantation. 24(1). 78–85. 7 indexed citations
15.
Kenkre, Vaishalee P. & Brad S. Kahl. (2012). The Future of B-Cell Lymphoma Therapy: The B-Cell Receptor and its Downstream Pathways. Current Hematologic Malignancy Reports. 7(3). 216–220. 14 indexed citations
16.
Kenkre, Vaishalee P. & Brad S. Kahl. (2012). What Is the Best Initial Therapy for a Patient With Symptomatic Low-Grade Follicular Lymphoma?. The Cancer Journal. 18(5). 383–389. 5 indexed citations
17.
Kenkre, Vaishalee P., Jens C. Eickhoff, Jules H. Blank, et al.. (2011). Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leukemia & lymphoma. 52(9). 1675–1680. 30 indexed citations
18.
Kenkre, Vaishalee P. & Brad S. Kahl. (2010). Follicular lymphoma: emerging therapeutic strategies. Expert Review of Hematology. 3(4). 485–495. 1 indexed citations
19.
20.
Kenkre, Vaishalee P. & Sonali M. Smith. (2008). Management of relapsed diffuse large B-cell lymphoma. Current Oncology Reports. 10(5). 393–403. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuqin Song Breakdown of academic impact, for papers by Emanuele Cencini Breakdown of academic impact, for papers by Maria Delioukina Breakdown of academic impact, for papers by Gottfried von Keudell Breakdown of academic impact, for papers by Guido Parvis Breakdown of academic impact, for papers by Greg Dueck Breakdown of academic impact, for papers by Finlay MacDougall Breakdown of academic impact, for papers by Dominique Penther Breakdown of academic impact, for papers by Junji Hiraga Breakdown of academic impact, for papers by Haiwen Huang
Rankless by CCL
2026